Form 990 for tax year 2023
Filed by SANSUM DIABETES RESEARCH INSTITUTE.
What the amendment changed
Compared with the return it replaced , filed 7 October 2024. matched by us Only the return's totals, a 990-PF's accounting method and the names listed in Part VII (Part VIII on a 990-PF) are compared. We relate returns by organization, tax year and form, and order them by each return's own timestamp; the filer's own "amended return" checkbox is a separate fact.
Listed only on the later return
- Andrew Koutnik
- Brad Webb
Listed under a different title
- Christian Farfan: Clinical Trial MGR, Senior Clinical Tr then Senior Clinical Tr
Totals
- Total revenue
- $10,639,114
- Total expenses
- $6,651,715
- Contributions and grants received
- $6,445,750
- Grants paid
- $0
- Program service revenue
- $3,195,041
- Investment income
- $85,334
- Other revenue
- $912,989
- Total assets, end of year
- $27,583,956
- Total liabilities, end of year
- $1,423,972
- Net assets or fund balances, end of year
- $26,159,984
- Program services expenses (Part IX)
- $4,743,855
- Management and general expenses
- $1,119,884
- Fundraising expenses
- $787,976
- Program service expenses (Part III)
- $4,743,855
Program services were 71.3% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1f · All other contributions, gifts and grants
$6,445,750
-
1g · Noncash contributions included above
$23,988
-
2a · Program service revenue: Patient Care Fees
total $51,650 · related or exempt $51,650
-
2b · Program service revenue: Research Contracts
total $3,143,391 · related or exempt $3,143,391
-
3 · Investment income
total $406,063 · excluded $406,063
-
4 · Income from investment of tax-exempt bond proceeds
total $0
-
5 · Royalties
total $871,251 · excluded $871,251
-
6a · Gross rents
real property $71,665
-
6c · Rental income or loss
real property $71,665
-
6d · Net rental income or loss
total $71,665 · related or exempt $71,665
-
7a · Gross sales of assets other than inventory
securities $2,014,260
-
7b · Less cost or other basis and sales expenses
securities $2,334,989
-
7c · Gain or loss
securities -$320,729
-
7d · Net gain or loss
total -$320,729 · related or exempt -$320,729
-
8a · Fundraising events: gross income
$65,375
-
8b · Fundraising events: direct expenses
$108,384
-
8c · Net income from fundraising events
total -$43,009 · excluded -$43,009
-
9c · Net income from gaming
total $0
-
10c · Net income from sales of inventory
total $0
-
11a · Other revenue: Other
total $13,082 · related or exempt $13,082
-
11e · Other revenue, total
$13,082
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $0
-
2 · Grants to domestic individuals
total $0
-
3 · Grants to foreign organizations and individuals
total $0
-
4 · Benefits paid to or for members
total $0
-
5 · Compensation of officers, directors and key employees
total $894,190 · program services $692,306 · management and general $113,762 · fundraising $88,122
-
6 · Compensation of disqualified persons
total $0
-
7 · Other salaries and wages
total $2,627,621 · program services $1,978,133 · management and general $301,375 · fundraising $348,113
-
8 · Pension plan contributions
total $85,390 · program services $55,824 · management and general $11,962 · fundraising $17,604
-
9 · Other employee benefits
total $201,648 · program services $134,598 · management and general $35,623 · fundraising $31,427
-
10 · Payroll taxes
total $255,441 · program services $191,982 · management and general $31,313 · fundraising $32,146
-
11a · Fees: management
total $0
-
11b · Fees: legal
total $11,412 · management and general $11,412
-
11c · Fees: accounting
total $24,000 · management and general $24,000
-
11d · Fees: lobbying
total $0
-
11e · Fees: professional fundraising services
total $0
-
11f · Fees: investment management
total $30,258 · management and general $30,258
-
11g · Fees: other
total $745,844 · program services $318,134 · management and general $406,913 · fundraising $20,797
-
12 · Advertising and promotion
total $62,988 · program services $3,311 · management and general $2,597 · fundraising $57,080
-
13 · Office expenses
total $94,869 · program services $55,873 · management and general $21,589 · fundraising $17,407
-
14 · Information technology
total $230,759 · program services $152,384 · management and general $30,100 · fundraising $48,275
-
15 · Royalties
total $286,088 · program services $286,088
-
16 · Occupancy
total $150,949 · program services $95,988 · management and general $40,994 · fundraising $13,967
-
17 · Travel
total $91,158 · program services $70,325 · management and general $16,878 · fundraising $3,955
-
18 · Travel or entertainment for public officials
total $0
-
19 · Conferences, conventions and meetings
total $39,749 · program services $32,676 · management and general $3,692 · fundraising $3,381
-
20 · Interest
total $0
-
21 · Payments to affiliates
total $0
-
22 · Depreciation, depletion and amortization
total $108,733 · program services $81,550 · management and general $15,222 · fundraising $11,961
-
23 · Insurance
total $87,136 · program services $57,453 · management and general $22,194 · fundraising $7,489
-
24a · Other expenses: Subject Reimbursement
total $351,769 · program services $351,769
-
24b · Other expenses: Lab Supplies
total $185,461 · program services $185,461
-
24c · Other expenses: Campaign Expenses
total $86,252 · fundraising $86,252
-
24e · All other expenses
total $0
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $247,231 · end of year $451,787
-
2 · Savings and temporary cash investments
beginning of year $4,343,578 · end of year $5,192,133
-
3 · Pledges and grants receivable
beginning of year $2,602,222 · end of year $6,268,701
-
4 · Accounts receivable
beginning of year $667,147 · end of year $580,057
-
5 · Loans and receivables from officers and key people
end of year $0
-
6 · Loans and receivables from disqualified persons
end of year $0
-
7 · Other notes and loans receivable
end of year $0
-
8 · Inventories for sale or use
end of year $0
-
9 · Prepaid expenses and deferred charges
beginning of year $45,457 · end of year $48,302
-
10a · Land, buildings and equipment: cost or other basis
$4,846,735
-
10b · Land, buildings and equipment: accumulated depreciation
$3,152,957
-
10c · Land, buildings and equipment, net
beginning of year $1,258,101 · end of year $1,693,778
-
11 · Investments: publicly traded securities
beginning of year $8,543,672 · end of year $9,086,989
-
12 · Investments: other securities
end of year $0
-
13 · Investments: program-related
end of year $0
-
14 · Intangible assets
end of year $0
-
15 · Other assets
beginning of year $4,467,173 · end of year $4,262,209
-
17 · Accounts payable and accrued expenses
beginning of year $484,434 · end of year $963,703
-
19 · Deferred revenue
beginning of year $55
-
25 · Other liabilities
beginning of year $731,821 · end of year $460,269
-
27 · Net assets without donor restrictions
beginning of year $9,340,642 · end of year $9,588,974
-
28 · Net assets with donor restrictions
beginning of year $11,617,629 · end of year $16,571,010
Mission and programs · 2023
Mission
Dedicated to improving the lives of people impacted by diabetes through research, education and care.
-
RESEARCHRESEARCH TYPE 1 DIABETES:SANSUM DIABETES RESEARCH INSTITUTE (SDRI) IS A GLOBAL LEADER IN ADVANCING RESEARCH, EDUCATION, AND CLINICAL CARE TO THOSE IMPACTED BY TYPE 1 DIABETES (T1D). SDRI IS A PREFERRED SITE FOR CLINICAL TRIALS, A TESTAMENT TO OUR EXCEPTIONAL RESEARCH CAPABILITIES AND COMMITMENT TO ADVANCING DIABETES CARE. IN 2023, SDRI CONDUCTED 29 CLINICAL RESEARCH TRIALS, AND ENGAGED OVER 700 PARTICIPANTS. CURRENT INDUSTRY PARTNERS INCLUDE ABBOTT, DEXCOM, INSULET, ELI LILLY, MANNKIND, MEDTRONIC DIABETES, NOVO NORDISK, SANOFI, TANDEM DIABETES CARE, AND MORE.AS A PREFERRED INDUSTRY PARTNER, SDRI IS COMMITTED TO CONDUCTING PIVOTAL CLINICAL RESEARCH STUDIES TO EVALUATE THE ACCURACY AND EFFICACY OF DIABETES MANAGEMENT DEVICES, INCLUDING CONTINUOUS GLUCOSE MONITORS AND INSULIN PUMPS. THESE ADVANCEMENTS HAVE REVOLUTIONIZED T1D MANAGEMENT BY PROVIDING REAL-TIME ADJUSTMENTS AND REDUCING THE MENTAL BURDEN OF LIVING WITH DIABETES. SDRI WILL CONTINUE PARTNERING WITH INDUSTRY TO CREATE THE BEST QUALITY OF LIFE POSSIBLE FOR THOSE LIVING WITH DIABETES.SDRI SERVED AS A CLINICAL SITE IN THE TRIALS FOR MEDTRONICS CLOSED-LOOP TECHNOLOGY, TANDEM DIABETES CONTROL- IQ AND BASAL-IQ TECHNOLOGY, AND INSULETS AUTOMATED INSULIN DELIVERY SYSTEM OMNIPOD 5.GIVEN THAT INSULIN REMAINS A CORNERSTONE IN T1D MANAGEMENT, SDRI CONDUCTS COMPREHENSIVE STUDIES TO EXPLORE NOVEL INSULIN FORMULATIONS, DELIVERY METHODS, AND DOSING STRATEGIES. SDRI HAS PARTICIPATED IN KEY DRUG DEVELOPMENT CLINICAL TRIALS INCLUDING MANNKIND'S AFREZZA INHALED INSULIN, ELI LILLY'S ONCE-WEEKLY BASAL INSULIN AND GLP-1 INHIBITORS, NOVO NORDISK'S FAST ACTING INSULIN FIASP AND COMPARING TRESIBA AND LANTUS OVER LONG-HAUL TRAVEL, AND A COMPARISON BETWEEN SANOFI'S DRUGS, TOUJEO AND LANTUS. BY STAYING AT THE FOREFRONT OF INSULIN RESEARCH, WE AIM TO OPTIMIZE TREATMENT OUTCOMES AND MINIMIZE THE BURDEN OF DIABETES MANAGEMENT.SDRIS MEANINGFUL RESEARCH PROVIDES VALUABLE INSIGHTS THAT ENHANCE THE QUALITY OF LIFE FOR INDIVIDUALS LIVING WITH T1D.RESEARCH TYPE 2 DIABETES:SDRI IS COMMITTED TO CONDUCTING GROUNDBREAKING RESEARCH TO FIND THE NEXT BREAKTHROUGH IN MANAGING TYPE 2 DIABETES (T2D), AS IT IS ONE OF THE FASTEST GROWING CHRONIC DISEASES IN THE WORLD. WE UNDERSTAND THAT EDUCATION PLAYS A VITAL ROLE IN LIVING WITH T2D. OUR TEAM IS COMMITTED TO OFFERING A HOLISTIC APPROACH IN MANAGING T2D WITH A SPECIAL INTEREST IN ADVANCING EDUCATION AND RESEARCH OPPORTUNITIES FOR UNDERSERVED COMMUNITIES.IN 2023, SDRI CONDUCTED EDUCATION, DIABETES IN PREGNANCY, AND DEVICE CLINICAL RESEARCH STUDIES THAT HELPED IMPROVE THE CARE AND MANAGEMENT OF TYPE 2 DIABETES, LEADING TO BETTER HEALTH OUTCOMES AND QUALITY OF LIFE FOR PATIENTS. SDRI PROUDLY PARTNERED WITH ROOTED SANTA BARBARA COUNTY IN 2023 IN THE PRODUCTION OF A CULTURALLY TAILORED, PLANT-BASED NUTRITION CURRICULUM THAT AIMS TO IMPROVE THE HEALTH AND HEALTH EQUITY OF SOCIOECONOMICALLY DISADVANTAGED POPULATIONS IN SANTA BARBARA. SDRI EQUIPPED OUR COMMUNITY HEALTH WORKERS WITH NEARLY 30 HOURS OF COMPREHENSIVE TRAINING AT THE UNIVERSITY OF SOUTHERN CALIFORNIA IN 2023, WHERE THEY GAINED ESSENTIAL KNOWLEDGE AND SKILLS TO SUPPORT CLINICAL RESEARCH RECRUITMENT, ENSURE MEDICATION SAFETY, AND IMPROVE DIABETES MANAGEMENT WITH THE LOCAL LATINO COMMUNITY. IN 2023, SDRI PROVIDED INDIVIDUAL CARE TO 87 UNDERREPRESENTED LATINOS WHO WERE LIVING WITH PREDIABETES, TYPE 2 DIABETES, OR DIABETES IN PREGNANCY. SDRI CONTINUED TO LEAD THE SANTA BARBARA NUTRITION HEALTH COALITION IN 2023 IN DEVELOPING AND IMPLEMENTING INNOVATIVE, CULTURALLY SENSITIVE, COMMUNITY-BASED, AND EVIDENCE-BASED NUTRITION INTERVENTION PROGRAMS TO IMPROVE HEALTH AND HEALTH EQUITY OF VULNERABLE POPULATIONS LIVING IN SANTA BARBRA COUNTY.
Expenses $4,595,932 · Revenue $3,134,391
-
CLINICAL CARE:SDRI PROVIDED CLINICAL CARE IN 3 AREAS: DIABETES IN PREGNANCY, PEDIATRIC AND ADULT ENDOCRINOLOGY.FOR NEARLY 50 YEARS, SDRI HAS REMAINED A THOUGHT LEADER FOR DIABETES DURING PREGNANCY. OUR TEAM IS COMMITTED TO CONDUCTING GROUNDBREAKING RESEARCH TO HELP REDUCE RISKS FOR A WOMANS PREGNANCY THAT IS COMPLICATED BY DIABETES. IN 2023, SDRI PROVIDED PATIENT CARE TO 120 PATIENTS WHOSE PREGNANCY WAS COMPLICATED BY ANY FORM OF DIABETES INCLUDING PREDIABETES, GESTATIONAL DIABETES, TYPE 1 DIABETES, AND TYPE 2 DIABETES. DURING APPOINTMENTS OUR ELITE TEAM OFFERED PATIENTS INNOVATIVE TOOLS TO HELP STABILIZE BLOOD GLUCOSE LEVELS TO LIMIT COMPLICATIONS TO BOTH THE EXPECTANT MOTHER AND BABY. SDRI PARTNERS WITH THE SANTA BARBARA COUNTY HEALTH DEPARTMENT TO ENSURE THAT UNDERREPRESENTED LATINA WOMEN RECEIVE SUPERIOR CARE FOR THEIR PREGNANCY COMPLICATED BY DIABETES. IN 2023, SDRI INITIATED THREE TRANSFORMATIONAL RESEARCH STUDIES CRITICAL TO DIAGNOSING AND MANAGING DIABETES IN PREGNANCY, IMPROVING HEALTH OUTCOMES, AND ENHANCING THE LIFESPAN OF MOTHERS AND THEIR BABIES. SDRI SERVED AS A CLINICAL RESEARCH SITE FOR THE FIRST AT HOME USE OF A PREGNANCY SPECIFIC CLOSED-LOOP SYSTEM. IN COLLABORATION WITH HARVARD JOHN A. PAULSON SCHOOL OF ENGINEERING AND APPLIED SCIENCES AT HARVARD UNIVERSITY, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, AND THE MAYO CLINIC. THIS STUDY, PUBLISHED IN DIABETES CARE, DEMONSTRATED THAT IN 2023, THE TRIAL DEMONSTRATED THAT THE SYSTEM IMPROVED BLOOD SUGAR CONTROL WITHOUT INCREASING RISKS, INDICATING IT CAN SAFELY HELP PREGNANT WOMEN MANAGE THEIR BLOOD SUGAR TARGETS AT HOME. THE STUDY RESULTS WERE PRESENTED AT THE ADVANCED TECHNOLOGIES AND TREATMENTS FOR DIABETES 2023 INTERNATIONAL DIABETES CONGRESS. SDRI IS PROUD TO PLAY A CRITICAL ROLE IN ENSURING THE HEALTH SPAN AND LIFESPAN OF WOMEN WHOSE PREGNANCIES ARE COMPLICATED BY DIABETES, AS WELL AS THEIR BABIES.
Expenses $118,923 · Revenue $51,650
-
EDUCATION AND COMMUNITY OUTREACH:CONTINUING THE LEGACY OF FOUNDER WILLIAM SANSUM, MD, SDRI HAS REMAINED COMMITTED TO PROVIDING LIFE-SAVING DIABETES CARE TO THE COMMUNITY, ENSURING THAT COST IS NEVER A BARRIER. TO EXPAND OUR REACH IN SANTA BARBARA AND HELP ADDRESS DISPARITIES IN ACCESS TO CARE, SDRI BEGAN HOSTING MOBILE CLINICS IN 2023 AT VARIOUS LOCATIONS AND EVENTS THROUGHOUT THE CITY. THESE MOBILE CLINICS, RUN BY BILINGUAL COMMUNITY HEALTH WORKERS, PROVIDE AN OPPORTUNITY FOR ATTENDEES TO RECEIVE CULTURALLY APPROPRIATE DIABETES EDUCATION, TEST BLOOD GLUCOSE LEVELS, CALCULATE THEIR BODY MASS INDEX, AND GET CONNECTED TO NECESSARY RESOURCES.RECOGNIZING A GROWING NEED FOR DIABETES TREATMENT AND PREVENTION WITHIN THE LOCAL LATINO POPULATION, IN 2023, SDRI SECURED A PERMANENT SPACE AT LA CASA DE LA RAZA, A PLACE WHERE SANTA BARBARAS LATINO COMMUNITY CAN CONGREGATE, HOST EVENTS, ATTEND WORKSHOPS, AND RECEIVE ASSISTANCE FROM SEVERAL NONPROFITS. IN ADDITION TO HOSTING CLINICS WEEKLY AT LA CASA, SDRI PROVIDED HEALTH SCREENINGS AND DIABETES EDUCATION AT SEVERAL OTHER LOCATIONS THROUGHOUT THE YEAR INCLUDING THE EASTSIDE LIBRARY, CARPINTERIA CHILDRENS PROJECT, AND THE SENIOR EXPO OF SANTA BARBARA AT EARL WARREN SHOWGROUNDS.SDRI CREATED A SERIES OF EDUCATION CLASSES FOR THE LATINO POPULATION INCLUDING: OCHO PASOS - 8 WEEKS TO HEALTHY LIVING, SEMILLAS DE CAMBIO - OCHO PASOS DURING PREGNANCY, AND GRUPO DE APOYO SPANISH PROGRAM FOR INDIVIDUALS LIVING WITH, OR AT RIS OF DEVELOPING, TYPE 2 DIABETES.COMMUNITY HEALTH WORKERS PLAY A VITAL ROLE IN OUR EFFORTS TO PROMOTE HEALTH EQUITY BY BRIDGING GAPS IN HEALTHCARE ACCESS AND EDUCATION. THESE DEDICATED INDIVIDUALS ARE TRAINED AT SDRI TO BECOME SPECIALISTS IN DIABETES AND RESEARCH PROGRAMS, WORKING CLOSELY WITH COMMUNITY MEMBERS TO PROVIDE CULTURALLY COMPETENT CARE, SUPPORT SELF-MANAGEMENT PRACTICES, AND EMPOWER INDIVIDUALS TO TAKE CONTROL OF THEIR HEALTH AND DIABETES. IN 2023, SDRI OFFERED ONETALK A PROGRAM WHERE PARTICIPANTS IMPACTED BY T!D SHARE THEIR IDEAS, EXPERIENCE AND EXPLORE WAYS TO ENHANCE THEIR HEALTH AND LIFESTYLE; LADATALK A PROGRAM FOR THOSE IMPACTED BY LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA) AND OFFERS INSIGHTS, CONNECTIONS, AND UP-TO-DATE INFORMATION ON CLINICAL RESEARCH TRIALS FROM SDRIS CLINICAL RESEARCH TEAM; FAMILY OUTREACH EVENTS - QUARTERLY EVENTS TO SUPPORT THE DIABETES COMMUNITY, WHERE FAMILIES CONNECT WITH OTHERS LIVING WITH TYPE 1 DIABETES, SHARE EXPERIENCES, AND LEARN ABOUT CURRENT CLINICAL TRIALS FROM SDRIS CLINICAL RESEARCH TEAM.
Expenses $29,000 · Revenue $9,000
As filed on the 2023 return.
Listed in Part VII
-
Kristin Castorino DO
Research Physician
- Total calculated
- $288,675
- From this org
- $266,900
- From related orgs
- $0
- Other
- $21,775
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $266,900
- Bonus
- not reported
- Other
- not reported
- Deferred
- $13,480
- Nontaxable benefits
- $8,295
- Filer's total
- $288,675
-
Raul Bastarrachea
Senior Research Scientist
- Total calculated
- $224,129
- From this org
- $196,238
- From related orgs
- $0
- Other
- $27,891
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $196,238
- Bonus
- not reported
- Other
- not reported
- Deferred
- $10,369
- Nontaxable benefits
- $17,522
- Filer's total
- $224,129
-
Ellen Goodstein
Executive Dir.
- Total calculated
- $220,305
- From this org
- $208,997
- From related orgs
- $0
- Other
- $11,308
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $201,496
- Bonus
- $7,501
- Other
- not reported
- Deferred
- $10,450
- Nontaxable benefits
- $858
- Filer's total
- $220,305
-
Kristen Nelson
Senior Clinical Nurse Practitioner
- Total calculated
- $161,081
- From this org
- $140,962
- From related orgs
- $0
- Other
- $20,119
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $140,962
- Bonus
- not reported
- Other
- not reported
- Deferred
- $7,231
- Nontaxable benefits
- $12,888
- Filer's total
- $161,081
-
Mei Mei Church
Nurse Practitioner
- Total calculated
- $144,716
- From this org
- $136,957
- From related orgs
- $0
- Other
- $7,759
- Hours/week
- 40
-
Kara Hornbuckle
Dir Development
- Total calculated
- $139,082
- From this org
- $130,517
- From related orgs
- $0
- Other
- $8,565
- Hours/week
- 40
-
Ashley Thorsell
Research Physician
- Total calculated
- $133,508
- From this org
- $123,750
- From related orgs
- $0
- Other
- $9,758
- Hours/week
- 40
-
Christian Farfan
Senior Clinical Tr
- Total calculated
- $128,600
- From this org
- $122,417
- From related orgs
- $0
- Other
- $6,183
- Hours/week
- 40
-
Andrew Koutnik
Research Scientist
- Total calculated
- $119,204
- From this org
- $118,293
- From related orgs
- $0
- Other
- $911
- Hours/week
- 40
-
Alexander DePaoli MD
Immed Past Pres
- Total calculated
- $15,263
- From this org
- $15,263
- From related orgs
- $0
- Other
- $0
- Hours/week
- 2
-
Kenneth Waxman MD FACS
President
- Total calculated
- $0
- Hours/week
- 4
-
James Sloan
VP/Treasurer
- Total calculated
- $0
- Hours/week
- 2
-
Joan Doell Arnold
Secretary
- Total calculated
- $0
- Hours/week
- 2
-
Miguel Avila
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Daniel Berger MD
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Anthony Castillo
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Lindsey Duca PhD
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Elena Engel
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Steven Jung Esq
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Norman Kurland
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Robert Nagy MD
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Flint Ogle
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Michael Paskin
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Miguel Rodriguez
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Matthew Rowe CIMA
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Wendy Thies Sell
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Mark Simon
Trustee
- Total calculated
- $0
- Hours/week
- 4
-
Sandra Tillisch Svoboda RN
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Brad Webb
Trustee
- Total calculated
- $0
- Hours/week
- 1
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Written employment contract
- 3 · Approval by the board or compensation committee
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
No itemized grants to organizations on this return.
Provenance
- Return type
- form_990
- Tax year
- 2023
- Filed
- 21 November 2024
- IRS schema version
- 2023v5.1
- Source object
- 202443269349301459
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.